Company / Cash & Equivalents
Aligos Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$18.3M
FY2025
5-year range
$18.3M / $186.8M
FY2021-FY2025
Trend
-50.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $136M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of -39.2%.
Declined from $136M to $18M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -39.2%
- 5-Year CAGR
- -39.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -39.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 50.5% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.3M | -50.5% |
| FY2024 | $37.0M | -72.7% |
| FY2023 | $135.7M | +66.8% |
| FY2022 | $81.3M | -56.5% |
| FY2021 | $186.8M | -15.2% |
| FY2020 | $220.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026